I-iomazenil and 99m Tc-ethyl cysteinate dimer (ECD) display central benzodiazepine receptors that are widely distributed in the normal brain cortex, a combination of brain perfusion, enzymatic activity and blood-brain barrier function, respectively. This report describes the case of a 30-year-old man who developed Lhermitte-Duclos disease. The mass regrew after a subtotal removal 13 years earlier. The cerebellar lesion exhibited hyperperfusion and hypermetabolism on blood flow and a metabolic rate of oxygen imaging on 15 O-gas positron emission tomography (PET), as well as a hyperactivity and a defect in the uptake on 99m Tc-ECD and 123 I-iomazenil SPECT imaging, respectively. The present Lhermitte-Duclos lesion might have the biological characteristics of both hypertrophy and neoplasm, from the perspective of results from 15 O-gas PET, 99m Tc-ECD and 123 Iiomazenil SPECT.
Introduction
Lhermitte-Duclos disease is a rare disorder characterized by a slowly enlarging mass in the cerebellum. The mass rarely regrows after surgical removal. The exact nature of the lesion is unclear, but it has variously been characterized as hypertrophy, hamartoma or benign neoplasm [1] [2] [3] [4] .
Positron emission tomography (PET) with 15 O can be used to obtain information regarding cerebral blood flow and oxygen metabolism [5] . In addition, 123 I-iomazenil and 99m Tcethyl cysteinate dimer (ECD) single-photon emission tomography (SPECT) display central benzodiazepine receptors that are widely distributed in the normal brain cortex [5, 6] and a combination of brain perfusion, enzymatic activity and blood-brain barrier function [7, 8] , respectively. These forms of emission tomography imaging can thus offer valuable assistance in studying the biological characteristics of brain tumors [1-4, 7, 8] .
We previously reported a case involving a patient with Lhermitte-Duclos disease in which a cerebellar lesion exhibited hyperperfusion on 15 O-water PET and hyperactivity on 99m Tc-ECD SPECT, suggesting that the lesion may represent hypertrophy or hamartoma rather than neoplasm [4] . The lesion in the present case regrew more than 10 years after surgical removal. We herein describe the biological characteristics of the regrowing lesion as evaluated using 15 O-gas PET, 99m Tc-ECD and 123 I-iomazenil SPECT.
Case Report
A 17-year-old man underwent a subtotal removal of a cerebellar mass lesion (Lhermitte-Duclos disease) via craniectomy [4] . Thirteen years later, the patient presented with headaches. Neurological examination showed a slightly ataxic gait. MRI revealed a regrowing mass lesion with an abnormal laminated pattern of cortical architecture in the left cerebellar hemisphere, extending to the vermis ( fig. 1 ).
Brain blood flow and metabolic rate of oxygen were calculated by the steady-state method using a PET scanner and 15 O-gas [5] . Both 99m Tc-ECD and 123 I-iomazenil SPECT studies were performed at 3 and 7 days after PET, respectively, using the same procedures applied in previous studies [4, 5] . The study protocol was approved by the local ethics committee. Written informed consent was obtained from the subject prior to undergoing these studies.
In the cerebellar region, increases in both blood flow and metabolic rate of oxygen were detected on 15 O-gas PET imaging ( fig. 2 ). While the lesion exhibited hyperactivity on 99m Tc-ECD SPECT imaging, where the contrast was similar to that of blood flow PET imaging, 123 Iiomazenil SPECT showed a defect in uptake within the lesion (fig. 2) .
The lesion was partially resected through a suboccipital craniectomy. Histological examination revealed typical features of Lhermitte-Duclos disease.
Discussion
Oxygen metabolic activity in brain tumors, including gliomas, is usually reduced and their metabolism is anaerobic (nonoxidative) [9] . In contrast, several studies using 18 Ffluorodeoxyglucose PET have shown a hypermetabolism in Lhermitte-Duclos lesions [1] [2] [3] , and the lesion in the present case exhibited increases in both blood flow and the metabolic rate of oxygen on 15 O-gas PET. Such findings suggest that Lhermitte-Duclos lesions aerobically metabolize glucose, and that this pathology may constitute of a hypertrophy rather than of a neoplasm.
As a lipophilic agent, 99m Tc-ECD penetrates the normal blood-brain barrier and is retained by a conversion of lipophilic molecules into hydrophilic compounds. The tracer is hydrolyzed to polar metabolites by de-esterification [4, 7, 8] . Slow or absent de-esterification leads to a lack of tracer retention, resulting in hypoactivity in 99m Tc-ECD SPECT, regardless of the increased blood flow [4, 7, 8] . Defective or decreased uptake of 99m Tc-ECD in almost all brain tumors thus indicates that this enzymatic process within the tumor tissues is usually absent or reduced [7, 8] . In contrast, in the present case, hyperactivity was detected in the lesion by 99m Tc-ECD SPECT, which provided an imaging contrast similar to that in blood flow PET. These findings were also similar to those obtained prior to resection of the original lesion 13 years earlier [4] , suggesting that the Lhermitte-Duclos lesion is enzymatically active and shows a blood-tissue barrier function equivalent to that of the normal neural tissue, and that these biological characteristics of hypertrophy in the Lhermitte-Duclos lesion can remain unchanged for 10 years or more.
Central benzodiazepine receptors are widely distributed in the normal brain cortex, including the cerebellum, and their distribution is displayed on 123 I-iomazenil SPECT [5, 6] . Our data demonstrated the absence of central benzodiazepine receptors in the lesion, suggesting that Lhermitte-Duclos lesions may represent a neoplasm rather than hamartoma or hypertrophy.
In conclusion, the present case of a Lhermitte-Duclos lesion regrowing 13 years after the initial removal might have shown the biological characteristics of both hypertrophy and neoplasm, from the perspective of results from 15 O-gas PET, 99m Tc-ECD and 123 I-iomazenil SPECT. 
